Hannah Kerr-Peterson

Transactional matters

• Advised Advent International and Warburg Pincus on their acquisition of Baxter International Inc.’s BioPharma Solutions business, a provider of sterile contract manufacturing solutions, parenteral delivery systems and customized support services to the pharma and biotech industries, for $4.25 billion
• Advised Elliott Investment Management, Patient Square Capital, and Veritas Capital on their acquisition of Syneos Health, a fully integrated biopharmaceutical solutions organisation offering clinical research and commercialisation services, for $7.1 billion
• Advised Partners Group on its investment in GHO Capital Partners’ portfolio company Sterling Pharma Solutions, a leading pharmaceutical development and manufacturing organisation
• Advised Partners Group on its acquisition of a majority stake in FairJourney Biologics, a leading antibody discovery contract research organisation, from GHO Capital Partners
• Advised Partners Group on its acquisition of Pharmathen, a contract development and manufacturing organisation specialised in advanced drug delivery technologies for complex generic pharmaceutical products, for €1.6 billion
• Advised Jounce Therapeutics, Inc. on its proposed all share merger with UK-headquartered biotech company Redx Pharma plc
• Advised Becton, Dickinson and Company on its acquisition of Edwards Lifesciences’ Critical Care business, a global leader in advanced monitoring solutions, for $4.2 billion
• Advised Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, in its sale to Sanofi for approximately $2.9 billion

Advisory matters

• Advised a global biotechnology company on an application for an Innovation Passport under the UK’s Innovative Licensing and Access Pathway
• Advised a clinical stage pharmaceutical company on how to position its developmental product as containing a new active substance
• Advised a consumer healthcare company on the reclassification of its contraceptive pill from prescription-only to pharmacy
• Advised various clients on borderline issues and the classification of their medical devices
• Advised a major online retailer on the establishment of a platform from which regulated products could be sold, such as human and veterinary medicines, medical devices and optical appliances*

Compliance matters

• Conducted an internal investigation for a major international pharmaceutical company into the use of unlawfully CE marked medical devices in it’s clinical trial
• Conducted various compliance investigations for a major international pharmaceutical company, concerning issues such as sponsorship of external events, hiring practices, expenses and hospitality
• Drafted a range of standard operating procedures/policies for various pharmaceutical companies concerning, for example, the engagement of HCPs, disease awareness campaigns and the delivery of virtual conferences
• Assisted a number of senior employees of an international pharmaceutical company, who were the focus of a Serious Fraud Office investigation into bribery and corruption overseas*
• Conducted an internal investigation for a biopharmaceutical company into allegations concerning the manipulation of prescribing software*

Commercial matters

• Drafted and negotiated an NHS supply agreement which comprised an entirely novel drug pricing mechanism
• Drafted and negotiated various clinical trial agreements, including those for investigator initiated trials, those involving contract research organisations and the gathering of real-world data/evidence
• Drafted and negotiated, on a pro bono basis, a series of research grant agreements on behalf of a cancer charity
• Drafted, on behalf of numerous clients, a range of templates including: master services agreements, speaker agreements, sponsorship agreements, MDR-compliant medical device import and distribution agreements, compounder agreements, collaboration agreements and distribution agreements

Contentious matters

• Assisted a global pharmaceutical company in its challenge of the Medicines and Healthcare products Regulatory Agency’s decision to include certain information in the authorisation documentation of a generic version of our client’s medicinal product
• Assisted various pharmaceutical companies with their defence of PMCPA complaints, related to allegations such as the promotion of prescription-only medicines on social media, the offer of inducements to healthcare professionals, and the publication of clinical trial results
• Assisted a multinational pharmaceutical company with its provision of information to, and cooperation with, the Infected Blood Inquiry*
• Assisted numerous clients with proceedings before the European Courts: T-33/17 Amicus Therapeutics UK Ltd; Amicus Therapeutics v European Medicines Agency; T-733/17 GMP-Orphan SA v European Commission and Appeal Case C-575/19P; T-337/18 Intercept Pharma Ltd, Intercept Pharmaceuticals Inc v European Medicines Agency*

*Experience prior to joining Ropes & Gray